| Not Yet Recruiting | Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones NCT06982222 | National Cancer Institute (NCI) | Phase 1 |
| Not Yet Recruiting | Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Pro NCT07466498 | University of Washington | Phase 2 |
| Recruiting | Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer NCT06616155 | University of Michigan Rogel Cancer Center | Phase 1 / Phase 2 |
| Recruiting | 177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate NCT07219147 | City of Hope Medical Center | Phase 1 |
| Recruiting | Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for NCT06931340 | Alliance for Clinical Trials in Oncology | Phase 3 |
| Recruiting | Addressing Health Literacy With a Tailored Survivorship Care Plan NCT06674863 | Emory University | N/A |
| Not Yet Recruiting | Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients NCT07200830 | Alliance for Clinical Trials in Oncology | Phase 3 |
| Recruiting | Imaging of Solid Tumors Using 18F-TRX NCT06942104 | Rahul Aggarwal | Phase 1 |
| Recruiting | Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Res NCT06526299 | University of Washington | Phase 2 |
| Recruiting | Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial NCT06632977 | Alliance for Clinical Trials in Oncology | Phase 2 |
| Recruiting | Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic C NCT06305598 | Roswell Park Cancer Institute | Phase 1 |
| Recruiting | Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Com NCT06470243 | SWOG Cancer Research Network | Phase 3 |
| Recruiting | Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistan NCT06236139 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Recruiting | Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer NCT06145633 | Fred Hutchinson Cancer Center | Phase 2 |
| Active Not Recruiting | Efficacy of Ra-223 in PSMA PET Optimally Selected Patients NCT05924672 | University of California, San Francisco | Phase 2 |
| Recruiting | Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPS NCT06288113 | Jonsson Comprehensive Cancer Center | Phase 2 |
| Recruiting | PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castrat NCT05805371 | City of Hope Medical Center | Phase 1 |
| Recruiting | Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, NCT06039371 | University of Washington | Phase 2 |
| Recruiting | Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer NCT06200103 | Mayo Clinic | Phase 2 |
| Recruiting | Image-Guided Biopsies to Identify Mechanisms of Resistance in Patients With Metastatic Castration Resistant Pr NCT05398302 | Jonsson Comprehensive Cancer Center | Phase 1 |
| Completed | Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant NCT05730712 | Mayo Clinic | Phase 2 |
| Withdrawn | Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Tre NCT05807126 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mu NCT05689021 | Mayo Clinic | Phase 2 |
| Recruiting | FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostat NCT06244004 | Northwestern University | Phase 2 |
| Active Not Recruiting | Testing the Effect of M1774 on Hard-to-Treat Refractory SPOP-mutant Prostate Cancer NCT05828082 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Se NCT05733351 | Emory University | Phase 1 |
| Active Not Recruiting | Testing Interruption of Hormonal Medications in Patients Responding Exceptionally to Therapy for Metastatic Pr NCT05241860 | Alliance for Clinical Trials in Oncology | Phase 2 |
| Withdrawn | Gallium-68 PSMA-11 PET in Participants With Prostate Cancer NCT05034562 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | 177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, T NCT05496959 | Jonsson Comprehensive Cancer Center | Phase 2 |
| Recruiting | Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer NCT05113537 | Vadim S Koshkin | Phase 1 / Phase 2 |
| Completed | 68Ga-PSMA-11 PET/CT Screening Prior to 177Lu-PSMA-617 Therapy for Patients With Metastatic Castrate Resistant NCT05547386 | Mayo Clinic | Phase 3 |
| Active Not Recruiting | Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, NCT05053152 | NRG Oncology | Phase 2 |
| Recruiting | Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoC NCT05168618 | University of Utah | Phase 2 |
| Terminated | Decitabine/Cedazuridine and Enzalutamide for the Treatment of Metastatic Castrate Resistant Prostate Cancer NCT05037500 | Roswell Park Cancer Institute | Phase 1 |
| Terminated | Treatment of Cancer-Related Bone Pain by Using Bone-Targeted Radiation-Based Therapy (Sn-117m-DTPA) in Patient NCT04616547 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate C NCT04455750 | Alliance for Clinical Trials in Oncology | Phase 3 |
| Completed | Pharmacokinetics of IA and IV Ga68-PSMA-11 Infusion NCT04976257 | Ryan Kohlbrenner, MD | EARLY_Phase 1 |
| Active Not Recruiting | 68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer NCT04716725 | Thomas Hope | Phase 2 |
| Terminated | 11C-YJH08 PET Imaging for Detection of Glucocorticoid Receptor Expression NCT04927663 | Rahul Aggarwal | Phase 1 |
| Terminated | Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer NCT04754425 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Ca NCT04915508 | Jonsson Comprehensive Cancer Center | Phase 2 |
| Terminated | 68Ga-PSMA-11 PET/CT for the Diagnosis of Bone Metastases in Patients With Prostate Cancer and Biochemical Prog NCT04928820 | Jonsson Comprehensive Cancer Center | Phase 2 |
| Active Not Recruiting | An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer NCT04777071 | University of Washington | Phase 2 |
| Recruiting | Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prosta NCT04734730 | City of Hope Medical Center | Phase 2 |
| Recruiting | Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant NCT04489719 | University of Washington | — |
| Withdrawn | Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer NCT03709550 | Roswell Park Cancer Institute | Phase 1 / Phase 2 |
| Active Not Recruiting | Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer NCT03902951 | Jonsson Comprehensive Cancer Center | Phase 2 |
| Recruiting | Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, t NCT04693377 | M.D. Anderson Cancer Center | N/A |
| Active Not Recruiting | ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer NCT04471974 | Rahul Aggarwal | Phase 2 |
| Withdrawn | Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the Treatment of Biochemica NCT04585932 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | National Cancer Institute "Cancer Moonshot Biobank" NCT04314401 | National Cancer Institute (NCI) | — |
| Recruiting | Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication NCT04071236 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Recruiting | Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET NCT04423211 | ECOG-ACRIN Cancer Research Group | Phase 3 |
| Active Not Recruiting | DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers NCT04388852 | M.D. Anderson Cancer Center | Phase 1 |
| Terminated | Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treatin NCT03649841 | University of Washington | Phase 2 |
| Active Not Recruiting | Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer NCT04267887 | OHSU Knight Cancer Institute | Phase 2 |
| Terminated | Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer NCT03999515 | University of Washington | Phase 2 |
| Terminated | Effect of Androgen Receptor Signaling Inhibitors on 68Ga-PSMA-11 PET/CT Imaging in Patients With Castration-Re NCT04279561 | Jonsson Comprehensive Cancer Center | Phase 1 |
| Recruiting | Modifying Metabolic Syndrome and Cardiovascular Risk for Prostate Cancer Patients on ADT Using a Risk Factor M NCT05054296 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes NCT04501913 | City of Hope Medical Center | — |
| Terminated | ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer NCT04159896 | Barbara Ann Karmanos Cancer Institute | Phase 2 |
| Unknown | sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer NCT04033432 | Northwestern University | Phase 2 |
| Terminated | An Investigational Scan (18F-Fluciclovine PET-CT) for the Measurement of Therapeutic Response in Patients With NCT04134208 | M.D. Anderson Cancer Center | Phase 4 |
| Active Not Recruiting | PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer NCT03873805 | City of Hope Medical Center | Phase 1 |
| Completed | Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate Cancer NCT03751436 | Roswell Park Cancer Institute | Phase 1 |
| Completed | A Phase I Study of SOR-C13 in Patients With Advanced Solid Tumors NCT03784677 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate C NCT03821792 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study NCT03707574 | National Cancer Institute (NCI) | — |
| Completed | Pharmacogenomics Testing in the Optimal Use of Supportive Care Medications in Stage III-IV Cancer NCT04067960 | Mayo Clinic | EARLY_Phase 1 |
| Recruiting | Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted NCT03866382 | National Cancer Institute (NCI) | Phase 2 |
| Withdrawn | Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Predicting Treatment Response NCT03581500 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With NCT03317392 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Recruiting | Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prosta NCT03678025 | SWOG Cancer Research Network | Phase 3 |
| Active Not Recruiting | PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutati NCT03218826 | National Cancer Institute (NCI) | Phase 1 |
| Completed | 68GA-PSMA-11 PET/CT Scan in Impacting Treatment Strategies for Patients With Prostate Cancer NCT04050215 | Jonsson Comprehensive Cancer Center | Phase 2 |
| Terminated | Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant NCT03360721 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | Genetic Testing for Men With Metastatic Prostate Cancer NCT03503097 | University of Washington | — |
| Active Not Recruiting | Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced NCT03217747 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prost NCT03204812 | M.D. Anderson Cancer Center | Phase 2 |